Staphylococcus epidermidis vaccine conjugate - Nabi

Drug Profile

Staphylococcus epidermidis vaccine conjugate - Nabi

Alternative Names: Staphylococcus epidermidis (PS-1) vaccine conjugate

Latest Information Update: 11 Jun 2008

Price : $50

At a glance

  • Originator Nabi Biopharmaceuticals
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 11 Jun 2008 Discontinued - Phase-I for Staphylococcal infections in USA (unspecified route)
  • 10 Feb 2006 Nabi Biopharmaceuticals has completed a phase I trial in Staphylococcal infections in USA
  • 27 May 2005 Phase-I clinical trials in Staphylococcal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top